Scope and claim-level patent landscape for US Patent 6,020,487 (olanzapine dihydrate Forms B and E and Form II process)
US Patent 6,020,487 is a crystalline solid-state IP package focused on olanzapine dihydrates identified by X-ray powder diffraction (XRPD) peak lists (interplanar spacings and relative intensities), plus substantially pure variants and a drying process to prepare “Form II” olanzapine. The independent claim core is a Form-selection claim to “olanzapine dihydrate selected from Dihydrate B and Dihydrate E,” followed by XRPD-defined crystalline embodiments and a process pathway using vacuum drying at about 40–70°C.
This is a high-specificity chemistry/solid-state estate. It is not a broad composition-of-matter around “any dihydrate,” but instead reads on two named crystalline dihydrates (B and E) and on a Form II preparation method that uses those dihydrates (and also expressly Dihydrate D in one process claim).
What is the scope of US Patent 6,020,487 claims for olanzapine dihydrate Forms B and E?
Headline scope. The patent claims (as provided) cover:
- A composition defined as olanzapine dihydrate selected from two specific crystalline forms: Dihydrate B or Dihydrate E.
- Crystalline sub-embodiments whose identity is established by XRPD “typical” peak positions (d-spacings) and, for one embodiment, peak relative intensities (I/I1).
- Substantially pure versions of Dihydrate B and Dihydrate E.
- A drying process to make “substantially pure Form II olanzapine,” where the starting material is one of the specified dihydrates (B, D, or E).
- Process temperature and equipment constraints (vacuum oven, ~40–70°C), plus optional narrowing to which dihydrate is used (B, D, or E).
Claim-by-claim mapping to legal coverage
Claim 1 (independent): “olanzapine dihydrate selected from Dihydrate B and Dihydrate E”
- Direct product coverage: any olanzapine dihydrate meeting the definitions of Dihydrate B or Dihydrate E falls within the literal scope.
- Not limited (by Claim 1 alone) to XRPD specifics, but those specifics are built into dependent claims 2 and 5 that further define particular crystalline embodiments.
Practical reading: Claim 1 is a form-selection capture. It is likely to become enforceable at the “dihydrate B/E” level rather than at the “any dihydrate” level.
Claim 2: Dihydrate B crystalline + XRPD d-spacing list
- Requires that the dihydrate is crystalline Dihydrate B and provides a specified set of d-spacings (Angstroms).
Impact on scope: This introduces a measurement-defined boundary. In litigation, the XRPD peak positions become central to whether the accused material is “crystalline Dihydrate B” as claimed.
Claim 3: Dihydrate B + XRPD relative intensity pattern
- Adds a second measurement layer: the XRPD pattern must include a set of relative intensity values for corresponding d-spacings.
Impact on scope: This claim reads on materials that not only match the peak positions but also fit the provided relative intensities profile. It is narrower than Claim 2.
Claim 4: Dihydrate B in substantially pure form
- Requires substantial purity. “Substantially pure” typically invites argument over impurity thresholds and crystallinity/phase purity, but the claim meaning is still measurement-driven.
Claim 5: Dihydrate E crystalline + XRPD d-spacing list
- Similar structure to Claim 2 but for crystalline Dihydrate E, with a smaller d-spacing set in the provided text.
Claim 6: Dihydrate E + XRPD relative intensity pattern
- Adds relative intensity requirements.
Claim 7: Dihydrate E in substantially pure form
- Adds the “substantially pure” constraint to Dihydrate E.
Claim 8: Process for preparing substantially pure Form II olanzapine
- Covers a process comprising: preparing an olanzapine dihydrate selected from Dihydrate B, Dihydrate D, and Dihydrate E and drying it until Form II is prepared.
- Key legal point: this claim is tied to the endpoint polymorphic/phase state (“Form II”) but defines the starting solid-state forms in the dihydrate family.
Claims 9–12: Drying conditions and narrowing by which dihydrate is used
- Claim 9: vacuum oven, about 40°C to about 70°C
- Claim 10: dihydrate is Dihydrate D
- Claim 11: dihydrate is Dihydrate B
- Claim 12: dihydrate is Dihydrate E
Impact on scope: Claim 9 is a practical manufacturing hook: drying conditions become an infringement lever. Claims 10–12 provide alternate routes, so an accused process cannot avoid liability by merely switching between B, D, and E, if the rest of the process elements match.
How do the XRPD claim requirements define Dihydrate B and Dihydrate E in US 6,020,487?
Claim technique. The patent uses XRPD “typical patterns” with two distinct layers:
- Peak positions: a defined list of d-spacings (Angstroms).
- Peak relative intensities: a defined list of I/I1 values paired to the d-spacings.
This is the core of enforceability because it converts an otherwise ambiguous polymorph/favourable crystallinity concept into an evidentiary target.
Dihydrate B XRPD boundary (from Claims 2 and 3)
Peak positions included (d, Å) (as provided):
9.9045, 6.9985, 6.7630, 6.4079, 6.1548, 6.0611, 5.8933, 5.6987, 5.4395, 5.1983, 5.0843, 4.9478, 4.7941, 4.6960, 4.5272, 4.4351, 4.3474, 4.2657, 4.1954, 4.0555, 3.9903, 3.9244, 3.8561, 3.8137, 3.7671, 3.6989, 3.6527, 3.5665, 3.4879, 3.3911, 3.3289, 3.2316, 3.1982, 3.1393, 3.0824, 2.9899, 2.9484, 2.9081, 2.8551, 2.8324, 2.7510, 2.7323, 2.6787, 2.6424, 2.5937.
Relative intensity profile included (I/I1) (as provided):
- 9.9045: 100.00
- 6.9985: 0.39
- 6.7630: 0.17
- 6.4079: 0.13
- 6.1548: 0.85
- 6.0611: 0.99
- 5.8933: 0.35
- 5.6987: 0.12
- 5.4395: 1.30
- 5.1983: 0.67
- 5.0843: 0.24
- 4.9478: 0.34
- 4.7941: 6.53
- 4.6960: 1.26
- 4.5272: 2.65
- 4.4351: 2.18
- 4.3474: 1.85
- 4.2657: 0.49
- 4.1954: 0.69
- 4.0555: 0.42
- 3.9903: 0.89
- 3.9244: 1.52
- 3.8561: 0.99
- 3.8137: 1.44
- 3.7671: 0.92
- 3.6989: 1.78
- 3.6527: 0.60
- 3.5665: 0.34
- 3.4879: 1.41
- 3.3911: 0.27
- 3.3289: 0.20
- 3.2316: 0.31
- 3.1982: 0.19
- 3.1393: 0.35
- 3.0824: 0.18
- 2.9899: 0.26
- 2.9484: 0.38
- 2.9081: 0.29
- 2.8551: 0.37
- 2.8324: 0.49
- 2.7510: 0.37
- 2.7323: 0.64
- 2.6787: 0.23
- 2.6424: 0.38
- 2.5937: 0.21
Litigation lever: A defendant attempting to design around would try to shift peak intensities or include additional phases that break the “typical” match, or adjust synthesis conditions to produce a different dihydrate or a mixed phase that does not qualify as “crystalline Dihydrate B” (or does not satisfy the stated pattern).
Dihydrate E XRPD boundary (from Claims 5 and 6)
Peak positions included (d, Å) (as provided):
9.8710, 9.5514, 6.9575, 6.1410, 6.0644, 5.9896, 5.8774, 4.7721, 4.6673, 4.5171, 4.4193, 4.3540, 4.2539, 4.2369, 4.0537, 4.0129, 3.8555, 3.7974, 3.6846, 3.5541, 3.4844, 3.4740, 3.4637, 3.3771, 3.1245, 2.9403.
Relative intensity profile included (I/I1) (as provided):
- 9.917: 100.00
- 9.6046: 16.75
- 7.0163: 2.44
- 6.1987: 8.78
- 6.0971: 10.62
- 5.9179: 1.73
- 4.8087: 50.14
- 4.7140: 10.24
- 4.5335: 14.20
- 4.4531: 7.80
- 4.3648: 3.04
- 4.2760: 4.50
- 4.0486: 2.76
- 3.8717: 5.09
- 3.8292: 13.39
- 3.7053: 17.24
- 3.5827: 4.82
- 3.4935: 13.22
- 3.3982: 2.01
- 3.3294: 1.30
- 3.2026: 0.98
- 3.1450: 2.66
- 3.1225: 1.63
- 3.0880: 2.11
- 2.9614: 2.49
- 2.9014: 1.03
- 2.8695: 2.06
- 2.8359: 1.63
- 2.7647: 1.95
- 2.7582: 1.68
- 2.7496: 1.84
- 2.7421: 1.03
- 2.7347: 1.36
- 2.6427: 2.01
Note for scope discipline: For Dihydrate E, the provided d-spacing list (Claim 5) and the provided intensity list (Claim 6) show slightly different values (for example, 9.8710 vs 9.917; and additional peaks in Claim 6 such as 6.1987). That mismatch can matter for claim construction and proof, because XRPD matching is evidence-heavy and dependent on how “typical” and measurement tolerances are treated.
Substantially pure claims (4 and 7)
Claims 4 and 7 narrow further by requiring “substantially pure” Dihydrate B/E. In practice, purity arguments typically center on:
- presence of other polymorphic/solvate phases,
- amorphous content,
- impurity levels,
- whether the sample is a single-phase crystalline material that matches the XRPD “typical” pattern.
What is claimed for preparing “Form II” olanzapine and how narrow is the process?
Core process claim (Claim 8):
- Start: an olanzapine dihydrate selected from Dihydrate B, Dihydrate D, or Dihydrate E.
- Operation: dry until Form II is prepared.
- Product/state: substantially pure Form II olanzapine.
Condition narrowing (Claim 9):
- Vacuum oven
- Temperature: about 40°C to about 70°C
Route selection (Claims 10–12):
- Claim 10: starting from Dihydrate D
- Claim 11: starting from Dihydrate B
- Claim 12: starting from Dihydrate E
Enforcement consequence: To infringe, an accused process must generally show:
- Starting material qualifies as one of the claimed dihydrates (or satisfies the XRPD-defined identity),
- Drying conditions include (at least) the vacuum oven and the temperature range if Claim 9 is asserted,
- The drying endpoint produces Form II and that final material is substantially pure.
Which other claims or patent families would typically overlap with US 6,020,487 in olanzapine solid forms?
US 6,020,487 is a crystallinity/XRPD and process-of-drying type of patent. In the olanzapine landscape, overlap commonly comes from three adjacency clusters:
- Other olanzapine polymorph/solvate patents that claim distinct forms by XRPD or DSC/other characterization.
- Process patents claiming how to make specific polymorphs or dihydrates, including solvent-mediated crystallization and dehydration steps.
- Form conversion method patents that claim conditions under which dihydrates convert to other solid-state forms.
However, the user-provided record includes only the claims, not bibliographic details (filing date, publication number, assignee, specification text) or the prosecution history. Without those, a definitive cross-reference mapping to sibling or later patents cannot be produced from the information available here.
When does US 6,020,487 lose exclusivity and when could generics enter under Hatch-Waxman?
No answer can be generated from the provided content alone because exclusivity timing depends on:
- patent filing date and priority,
- term adjustments,
- whether listed as an Orange Book patent for any listed NDA/ANDA product,
- regulatory/marketing status and any market exclusivity periods tied to a specific drug reference product.
Since the necessary bibliographic and regulatory listing data is not included, exclusivity and launch timing cannot be stated accurately.
What is the Orange Book status of US 6,020,487 and which FDA applications could be affected?
No answer can be produced from the provided content alone. Orange Book status requires the specific NDA/ANDA reference product and whether US 6,020,487 is listed as a drug substance or drug product patent for that listing. The provided record does not include:
- any NDA/ANDA number,
- listing type (drug substance vs drug product vs method of use),
- listed active ingredient or dosage form.
How strong is the patent estate for olanzapine dihydrate Forms B and E based on claim structure alone?
Claim-strength indicators from the provided text:
-
The claims are highly specific to crystalline forms and are evidence-defined by XRPD d-spacings and intensity patterns. That specificity can be a double-edged sword:
- It improves the ability to identify what falls within scope.
- It narrows the set of materials that satisfy “typical” patterns.
-
Independent Claim 1 is a form selection over B and E. That helps capture any embodiment that can be shown to match those forms, including mixtures, unless “substantially pure” is required by the specific asserted claim.
-
The process claims add a manufacturing hook (vacuum oven, 40–70°C). That tends to narrow infringement targets to process parameters that can be verified.
Claim hierarchy effect:
- Claims 2/5 (d-spacing lists) are narrower than Claim 1, and Claims 3/6 (relative intensity lists) are narrower still.
- Claims 4/7 (“substantially pure”) further narrow the product state.
- Process Claim 8 can be broader than Claims 9–12 if the vacuum temperature limitation is not asserted, but it still requires “Form II” formation and substantial purity.
What generic entry risks exist for manufacturers making olanzapine solid forms (Form II) from dihydrate intermediates?
Based on the claims provided, generic or API producers risk liability when they:
- produce olanzapine dihydrate intermediates that meet the Dihydrate B or Dihydrate E XRPD-defined identities, or
- convert such dihydrates into Form II using drying steps within the claimed method structure, especially with vacuum oven drying in the 40–70°C range (if Claim 9 is in play).
A key design-around lever is to change either:
- the solid-state identity of the intermediate (avoid qualifying as Dihydrate B/E/D per XRPD patterns), or
- the process conditions (operate outside the stated temperature or omit vacuum drying), or
- the endpoint (do not reach “substantially pure Form II” as defined in the asserted claim context).
How does US 6,020,487 compare with typical olanzapine polymorph claim strategies?
US 6,020,487 strategy in one line: it is an XRPD-list-defined crystalline-form claim set paired with a conversion/drying process claim.
Compared with broader strategies in solid-state portfolios:
- It is narrower than patents that claim “any dihydrate” or “any crystalline form exhibiting a general pattern.”
- It is narrower than purely structural claims not tied to specific peak lists.
- It is broader than claims that tie to one specific batch or one specific crystallization route, since it targets the material identity and the endpoint conversion rather than a detailed solvent recipe.
Key Data Table: US 6,020,487 claim coverage (from provided claim text only)
| Claim |
Coverage type |
Target |
Defining elements in provided text |
| 1 |
Composition |
Olanzapine dihydrate (selected) |
Dihydrate B or Dihydrate E |
| 2 |
Composition subset |
Crystalline Dihydrate B |
XRPD d-spacings list |
| 3 |
Composition subset |
Crystalline Dihydrate B |
XRPD d-spacings + relative intensity (I/I1) |
| 4 |
Composition subset |
Dihydrate B |
Substantially pure crystalline Dihydrate B |
| 5 |
Composition subset |
Crystalline Dihydrate E |
XRPD d-spacings list |
| 6 |
Composition subset |
Crystalline Dihydrate E |
XRPD d-spacings + relative intensity (I/I1) |
| 7 |
Composition subset |
Dihydrate E |
Substantially pure crystalline Dihydrate E |
| 8 |
Process |
Form II preparation |
Start: B/D/E dihydrate; drying until Form II prepared; “substantially pure” Form II |
| 9 |
Process subset |
Form II preparation |
Vacuum oven drying, about 40°C to about 70°C |
| 10 |
Process subset |
Form II preparation from D |
Starting dihydrate is Dihydrate D |
| 11 |
Process subset |
Form II preparation from B |
Starting dihydrate is Dihydrate B |
| 12 |
Process subset |
Form II preparation from E |
Starting dihydrate is Dihydrate E |
Key Takeaways
- US 6,020,487 is a solid-state IP patent centered on olanzapine dihydrate polymorph/solvate identities: Dihydrate B and Dihydrate E, defined through XRPD d-spacing lists and, for narrower claims, relative intensity patterns.
- The estate also covers a conversion process to produce substantially pure Form II by drying a qualifying dihydrate intermediate, with an explicit vacuum oven 40–70°C narrowing in dependent Claim 9.
- The enforceable boundaries are measurement-driven: XRPD peak position and intensity matching and purity of the final solid state are the likely technical battlegrounds.
- Exclusivity timing, Orange Book listing status, and generic entry windows cannot be determined from the claim text alone.
FAQs
-
What is the difference between US 6,020,487 Claims 2 and 3 for Dihydrate B?
Claim 2 requires an XRPD d-spacing list matching crystalline Dihydrate B; Claim 3 additionally requires an XRPD relative intensity (I/I1) pattern.
-
Does US 6,020,487 Claim 1 require the XRPD peak list?
Claim 1 defines the composition as olanzapine dihydrate selected from Dihydrate B or Dihydrate E; the specific XRPD peak lists appear in dependent claims (2 and 5) and intensity lists in dependent claims (3 and 6).
-
What drying parameters are explicitly claimed for making Form II?
Claim 9 limits drying to a vacuum oven at about 40°C to about 70°C.
-
Can a process start from Dihydrate D and still fall under US 6,020,487?
Yes. Claim 8 includes Dihydrate D among the starting dihydrates, and Claim 10 explicitly covers starting from Dihydrate D.
-
What does “substantially pure” add to the scope in this patent?
It narrows the product state for Claims 4, 7, and 8 to solids that are not only phase-identified by the XRPD criteria (where specified) but also meet a purity threshold.
References
- United States Patent 6,020,487. “Olanzapine dihydrate” (claims provided in prompt).
